Titre : Hémolysines

Hémolysines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cell Line
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hémolysines : Questions médicales les plus fréquentes", "headline": "Hémolysines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hémolysines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-22", "dateModified": "2025-04-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hémolysines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Perforines", "url": "https://questionsmedicales.fr/mesh/D052899", "about": { "@type": "MedicalCondition", "name": "Perforines", "code": { "@type": "MedicalCode", "code": "D052899", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.695" } } }, "about": { "@type": "MedicalCondition", "name": "Hémolysines", "alternateName": "Hemolysin Proteins", "code": { "@type": "MedicalCode", "code": "D006460", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Vanesa Herlax", "url": "https://questionsmedicales.fr/author/Vanesa%20Herlax", "affiliation": { "@type": "Organization", "name": "Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), CCT- La Plata, CONICET. Facultad de Ciencias Médicas. Universidad Nacional de La Plata, Argentina. Electronic address: vherlax@med.unlp.edu.ar." } }, { "@type": "Person", "name": "Li Li", "url": "https://questionsmedicales.fr/author/Li%20Li", "affiliation": { "@type": "Organization", "name": "Sichuan Animal Disease Prevention and Control Center, Chengdu 610041, China." } }, { "@type": "Person", "name": "Lucía Cané", "url": "https://questionsmedicales.fr/author/Luc%C3%ADa%20Can%C3%A9", "affiliation": { "@type": "Organization", "name": "Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), CCT- La Plata, CONICET. Facultad de Ciencias Médicas. Universidad Nacional de La Plata, Argentina." } }, { "@type": "Person", "name": "Pablo J Schwarzbaum", "url": "https://questionsmedicales.fr/author/Pablo%20J%20Schwarzbaum", "affiliation": { "@type": "Organization", "name": "Instituto de Química y Fisico-Química Biológicas (IQUIFIB) \"Prof. Alejandro C. Paladini\", Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina." } }, { "@type": "Person", "name": "Lin Wei", "url": "https://questionsmedicales.fr/author/Lin%20Wei", "affiliation": { "@type": "Organization", "name": "Changchun University of Chinese Medicine, Changchun, 130117, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.", "datePublished": "2023-06-10", "url": "https://questionsmedicales.fr/article/37308396", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.dld.2023.03.011" } }, { "@type": "ScholarlyArticle", "name": "Second-Generation Parenteral Antipsychotic (Olanzapine) as a First-Line Treatment for Acute Undifferentiated Agitation in the Emergency Department in Comparison With Haloperidol.", "datePublished": "2023-06-10", "url": "https://questionsmedicales.fr/article/37435257", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7759/cureus.40226" } }, { "@type": "ScholarlyArticle", "name": "Ecological risk assessment of the Paraíba River estuary (Brazil): Plan for a tier 1 screening phase for the ecotoxicological line of evidence.", "datePublished": "2023-06-04", "url": "https://questionsmedicales.fr/article/37279821", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.chemosphere.2023.139039" } }, { "@type": "ScholarlyArticle", "name": "Front-line hotel employees mental health and quality of life post COVID-19 pandemic: The role of coping strategies.", "datePublished": "2023-06-02", "url": "https://questionsmedicales.fr/article/37287607", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.heliyon.2023.e16915" } }, { "@type": "ScholarlyArticle", "name": "Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAF", "datePublished": "2023-05-05", "url": "https://questionsmedicales.fr/article/37213293", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fonc.2023.1166545" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Perforines", "item": "https://questionsmedicales.fr/mesh/D052899" }, { "@type": "ListItem", "position": 6, "name": "Hémolysines", "item": "https://questionsmedicales.fr/mesh/D006460" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hémolysines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hémolysines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-01", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hémolysines", "description": "Comment diagnostiquer une infection par hémolysines ?\nQuels tests sont utilisés pour détecter les hémolysines ?\nLes hémolysines sont-elles visibles sur une analyse sanguine ?\nQuels signes indiquent une hémolyse dans le sang ?\nPeut-on détecter les hémolysines par PCR ?", "url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Cell+Line&page=998#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hémolysines", "description": "Quels sont les symptômes d'une infection hémolytique ?\nComment l'hémolyse affecte-t-elle le corps ?\nY a-t-il des symptômes spécifiques aux hémolysines ?\nLes hémolysines provoquent-elles des réactions allergiques ?\nQuels signes cliniques sont associés à l'hémolyse ?", "url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Cell+Line&page=998#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hémolysines", "description": "Comment prévenir les infections par hémolysines ?\nLes personnes à risque doivent-elles prendre des précautions ?\nLes hémolysines peuvent-elles être évitées par l'alimentation ?\nLes mesures d'hygiène sont-elles suffisantes ?\nLes voyages à l'étranger augmentent-ils le risque d'hémolyse ?", "url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Cell+Line&page=998#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hémolysines", "description": "Quel traitement est recommandé pour une infection hémolytique ?\nComment traiter l'anémie causée par hémolyse ?\nLes corticostéroïdes sont-ils efficaces contre l'hémolyse ?\nY a-t-il des traitements préventifs pour les hémolysines ?\nQuand faut-il envisager une splénectomie ?", "url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Cell+Line&page=998#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hémolysines", "description": "Quelles complications peuvent survenir avec l'hémolyse ?\nL'hémolyse peut-elle entraîner des problèmes rénaux ?\nY a-t-il un risque de choc hypovolémique ?\nLes complications neurologiques sont-elles possibles ?\nComment gérer les complications liées à l'hémolyse ?", "url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Cell+Line&page=998#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hémolysines", "description": "Quels sont les facteurs de risque d'hémolyse ?\nLes personnes âgées sont-elles plus à risque ?\nLes maladies génétiques augmentent-elles le risque d'hémolyse ?\nLe stress peut-il influencer l'hémolyse ?\nLes transfusions sanguines augmentent-elles le risque d'hémolyse ?", "url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Cell+Line&page=998#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par hémolysines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic peut être établi par des tests sanguins et cultures bactériennes." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les hémolysines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests d'hémolyse sur milieux de culture et les tests sérologiques sont courants." } }, { "@type": "Question", "name": "Les hémolysines sont-elles visibles sur une analyse sanguine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Elles ne sont pas directement visibles, mais peuvent être détectées par des tests spécifiques." } }, { "@type": "Question", "name": "Quels signes indiquent une hémolyse dans le sang ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Une augmentation de la bilirubine et une diminution des globules rouges peuvent indiquer une hémolyse." } }, { "@type": "Question", "name": "Peut-on détecter les hémolysines par PCR ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la PCR peut être utilisée pour détecter les gènes codant pour les hémolysines." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une infection hémolytique ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, fatigue, et signes d'anémie comme pâleur." } }, { "@type": "Question", "name": "Comment l'hémolyse affecte-t-elle le corps ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "L'hémolyse peut entraîner une anémie, une jaunisse et des douleurs abdominales." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques aux hémolysines ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs lombaires et des urines foncées peuvent survenir en cas d'hémolyse." } }, { "@type": "Question", "name": "Les hémolysines provoquent-elles des réactions allergiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent provoquer des réactions immunitaires, mais pas des allergies classiques." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à l'hémolyse ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent tachycardie, hypotension et signes de choc dans les cas graves." } }, { "@type": "Question", "name": "Comment prévenir les infections par hémolysines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir une bonne hygiène et se faire vacciner contre les bactéries responsables." } }, { "@type": "Question", "name": "Les personnes à risque doivent-elles prendre des précautions ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées doivent éviter les contacts avec des sources d'infection." } }, { "@type": "Question", "name": "Les hémolysines peuvent-elles être évitées par l'alimentation ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée renforce le système immunitaire, mais ne prévient pas directement." } }, { "@type": "Question", "name": "Les mesures d'hygiène sont-elles suffisantes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont essentielles, mais doivent être combinées avec la vaccination pour une protection optimale." } }, { "@type": "Question", "name": "Les voyages à l'étranger augmentent-ils le risque d'hémolyse ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains pays présentent un risque accru d'infections hémolytiques, surtout sans vaccination." } }, { "@type": "Question", "name": "Quel traitement est recommandé pour une infection hémolytique ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les antibiotiques sont souvent prescrits pour traiter les infections causées par hémolysines." } }, { "@type": "Question", "name": "Comment traiter l'anémie causée par hémolyse ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des transfusions sanguines et des suppléments de fer peuvent être nécessaires." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils efficaces contre l'hémolyse ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent réduire l'inflammation et la destruction des globules rouges." } }, { "@type": "Question", "name": "Y a-t-il des traitements préventifs pour les hémolysines ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La vaccination contre certaines bactéries peut aider à prévenir les infections hémolytiques." } }, { "@type": "Question", "name": "Quand faut-il envisager une splénectomie ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une splénectomie peut être envisagée en cas d'hémolyse auto-immune sévère et réfractaire." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'hémolyse ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'anémie sévère, la jaunisse et des défaillances organiques." } }, { "@type": "Question", "name": "L'hémolyse peut-elle entraîner des problèmes rénaux ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'hémolyse peut provoquer une insuffisance rénale aiguë en raison de la libération de toxines." } }, { "@type": "Question", "name": "Y a-t-il un risque de choc hypovolémique ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une hémolyse massive peut entraîner un choc hypovolémique en raison de la perte de sang." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles possibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques peuvent survenir, notamment en cas d'anémie sévère prolongée." } }, { "@type": "Question", "name": "Comment gérer les complications liées à l'hémolyse ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion nécessite un traitement rapide des infections et un suivi médical régulier." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque d'hémolyse ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des maladies auto-immunes, des infections et des antécédents transfusionnels." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées ont un risque accru d'hémolyse en raison de la fragilité de leur système immunitaire." } }, { "@type": "Question", "name": "Les maladies génétiques augmentent-elles le risque d'hémolyse ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies génétiques, comme la sphérocytose, augmentent le risque d'hémolyse." } }, { "@type": "Question", "name": "Le stress peut-il influencer l'hémolyse ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut affaiblir le système immunitaire, augmentant ainsi le risque d'infections hémolytiques." } }, { "@type": "Question", "name": "Les transfusions sanguines augmentent-elles le risque d'hémolyse ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des transfusions incompatibles peuvent provoquer une hémolyse aiguë." } } ] } ] }

Sources (10000 au total)

Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.

There is no robust predictor of response to chemotherapy (CT) in unresectable pancreatic adenocarcinomas (UPA). The objective of the KRASCIPANC study was to analyze the kinetics of cell-free DNA (cfDN... Blood samples were collected just before first CT and at day 28. The primary endpoint was the kinetics of KRAS-mutated ctDNA by digital droplet PCR between D0 and D28 as a predictor of progression-fre... We analyzed 65 patients with a KRAS-mutated tumor. A high level of cfDNA and KRAS-mutated ctDNA at D0, as well as the presence of KRAS-mutated ctDNA at D28, were strongly associated with lower central... A combined score using cfDNA level at diagnosis and KRAS-mutated ctDNA at D28 is strongly associated with patient survival/response to chemotherapy in UPA.... ClinicalTrials.gov Identifier: NCT04560270....

Sulfonylureas as second line therapy for type 2 diabetes among veterans: Results from a National Longitudinal Cohort Study.

To assess if switching to or adding sulfonylureas increases major adverse cardiovascular events (MACE) or severe hypoglycemia versus remaining on metformin alone.... This was a retrospective, longitudinal cohort utilizing United States Veterans Health Administration and Medicare data. Veterans with type 2 diabetes on metformin monotherapy between 2004 and 2006 wer... Switching to or adding a sulfonylurea to metformin was associated with 3 times the risk of severe hypoglycemia versus metformin monotherapy (HR:3.44, 95% CI: 3.06,3.85 and HR: 3.08, 95% CI: 2.77,3.42,... Switching to and adding second-generation sulfonylureas was associated an increase in severe hypoglycemia and MACE versus remaining on metformin alone. In an era where guidelines recommend diabetes th...

STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.

Thymic malignancies are rare tumors with few therapeutic options. The STYLE trial was aimed to evaluate activity and safety of sunitinib in advanced or recurrent type B3 thymoma (T) and thymic carcino... In this multicenter, Simon 2 stages, phase 2 trial, patients with pretreated T or TC were enrolled in two cohorts and assessed separately. Sunitinib was administered 50 mg daily for 4 weeks, followed ... From March 2017 to January 2022, 12 patients with T and 32 patients with TC were enrolled. At stage 1, ORR was 0% (90% confidence interval [CI]: 0.0-22.1) in T and 16.7% (90% CI: 3.1-43.8) in TC, so t... This trial confirms the activity of sunitinib in patients with TC, supporting its use as a second-line treatment, albeit with potential toxicity that requires dose adjustment....

Factors associated with adherence and viral suppression among patients on second-line antiretroviral therapy in an urban HIV program in Kenya.

The aim of this study is to estimate the proportion of virologically suppressed People living with HIV on second-line ART and to identify factors associated with virologic suppression. With an increas... A retrospective study was conducted of patients on second-line ART in 17 facilities supported by University of Maryland, Baltimore, in Nairobi, Kenya, covering the period beginning October 2016 up to ... Of 1100 study participants with viral load data, 974 (88.5%) reported optimal adherence while on first-line ART and 1029 (93.5%) reported optimal adherence to second-line ART. Overall, viral load supp... Viral suppression remains high and adherence was strongly associated with viral suppression, underscoring the need to adequately address the barriers to adherence before switching regimens....

Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy.

Almost all patients with multiple myeloma (MM) will eventually develop disease that has relapsed with or become refractory to available treatments and will require additional therapy. However, data ar...